BACE1

BACE1

B-site amyloid precursor protein (APP) cleaving enzyme. An aspartic-acid protease encoded by BACE1 on chromosome 11q23.2.-q23.3, which is linked to the pathogenesis of Alzheimer's disease and the formation of myelin sheaths in peripheral nerve cells. BACE1 is a transmembrane aspartic protease (beta-secretase) found in the Golgi apparatus, trans-Golgi network, secretory vesicles, and endosomes. It cleaves amyloid precursor protein (APP) in the brain into amyloid beta peptide, a major component of the amyloid plaques of Alzheimer's disease (AD), the deposition of which is the central pathology in AD, for which BACE1 is potential therapeutic target.
Mentioned in ?
References in periodicals archive ?
BACE1 is transiently acetylated on lysine residues in the ER/ER-Golgi intermediate compartment.
reduction observed with MK-8931 may offer an opportunity to further understand the role BACE1 inhibition plays in the underlying pathology of Alzheimer's disease," said Darryle Schoepp, Ph.
Ginsenoside Rg1 attenuates beta-amyloid generation via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695 cells.
In vitro, the allele blocked the effect of BACE1, reducing the production of Abeta42 by up to 50%.
This suggests that a well-tolerated BACE1 inhibitor might have a place in any future Alzheimer's treatment regimen.
Hypoxia-inducible factor 'alpha (HIF-1 alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Reticulon family members modulate BACE1 activity and amyloid-[beta] peptide generation.
This is the first demonstration of the lowering of beta-amyloid levels by a BACE1 inhibitor in people with Alzheimer's disease," Forman said.
We observed an increase in ADAM10 and a decrease in BACE1 and APP695 protein levels and, subsequently, a reduction in A[beta] levels and A[beta] burden were present in HupA-treated mouse brain, suggesting that HupA enhances the nonamyloidogenic APP cleavage pathway.
Stefansson and his colleagues, it's easy to imagine how a new BACE1 inhibitor could be applied to a preclinical Alzheimer's population, with outcomes measured by the targets identified by Dr.
The study, performed in mice and utilizing post-mortem samples of brains from patients with Alzheimer's disease, identifies the complex mechanisms that result in a rapid and robust post-injury elevation of the enzyme, BACE1, in the brain.